JP2007517037A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517037A5
JP2007517037A5 JP2006547316A JP2006547316A JP2007517037A5 JP 2007517037 A5 JP2007517037 A5 JP 2007517037A5 JP 2006547316 A JP2006547316 A JP 2006547316A JP 2006547316 A JP2006547316 A JP 2006547316A JP 2007517037 A5 JP2007517037 A5 JP 2007517037A5
Authority
JP
Japan
Prior art keywords
carbons
alkyl
carbon atoms
group
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006547316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/043148 external-priority patent/WO2005066116A1/en
Publication of JP2007517037A publication Critical patent/JP2007517037A/ja
Publication of JP2007517037A5 publication Critical patent/JP2007517037A5/ja
Pending legal-status Critical Current

Links

JP2006547316A 2003-12-30 2004-12-21 RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム Pending JP2007517037A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53373303P 2003-12-30 2003-12-30
PCT/US2004/043148 WO2005066116A1 (en) 2003-12-30 2004-12-21 Disubstituted chalcone oximes as selective agonists of rarϝ retinoid receptors

Publications (2)

Publication Number Publication Date
JP2007517037A JP2007517037A (ja) 2007-06-28
JP2007517037A5 true JP2007517037A5 (https=) 2008-02-14

Family

ID=34748950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547316A Pending JP2007517037A (ja) 2003-12-30 2004-12-21 RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム

Country Status (6)

Country Link
US (1) US7476673B2 (https=)
EP (1) EP1704139A1 (https=)
JP (1) JP2007517037A (https=)
CA (1) CA2552090A1 (https=)
MX (1) MXPA06007560A (https=)
WO (1) WO2005066116A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881137B1 (fr) * 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ579431A (en) * 2007-03-09 2012-04-27 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
AU2010214607B2 (en) * 2009-02-10 2012-05-31 Nippon Soda Co., Ltd. Nitrogen-containing compounds and harmful organism control agents
CN101941919B (zh) * 2009-07-07 2014-07-02 天津药物研究院 一种制备顺式肟及肟醚衍生物的方法
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
US9062015B2 (en) 2009-12-14 2015-06-23 Merck Patent Gmbh Inhibitors of sphingosine kinase
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
CN108025075B (zh) * 2015-09-10 2020-09-22 国立大学法人冈山大学 炎症性呼吸器官疾病的预防或治疗用医药组合物
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
RU2742770C1 (ru) 2017-07-06 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное индола и формамида, способ его получения и применение в медицине
KR20200029544A (ko) 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
KR20200044889A (ko) 2017-08-31 2020-04-29 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
AU2018331125A1 (en) 2017-09-12 2020-03-05 Jiangsu Hengrui Medicine Co., Ltd. Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
EP3687482A1 (en) 2017-09-28 2020-08-05 Johnson & Johnson Consumer Inc. Cosmetic compositions and method of treating the skin
CA3139285A1 (en) * 2019-06-27 2020-12-30 Hangzhou Healzen Therapeutics Co., Ltd. Casein kinase 1e inhibitor, pharmaceutical composition and application thereof
JP2024541472A (ja) * 2021-11-23 2024-11-08 アイオー セラピューティクス インコーポレイテッド がん治療のためにRARγアゴニストを使用する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69224660C5 (de) 1991-12-18 2010-06-02 The Salk Institute For Biological Studies, La Jolla Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
RU2165423C2 (ru) * 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Полипептидное соединение, способ его получения и фармацевтическая композиция
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
US6313168B1 (en) * 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US6403810B2 (en) * 2000-07-10 2002-06-11 Hoffmann-La Roche Inc. Thiophene derivatives
US6303785B1 (en) * 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
DE60136477D1 (de) 2000-10-02 2008-12-18 Hoffmann La Roche Retinoide zur behandlung von emphysem
US20030003517A1 (en) 2001-03-22 2003-01-02 Klein Elliott S. Methods of detecting dissociated nuclear hormone receptor ligands
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
DE602004019685D1 (de) * 2003-12-26 2009-04-09 Allergan Inc DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR

Similar Documents

Publication Publication Date Title
JP2007517037A5 (https=)
JP2010530372A5 (https=)
JP2018135343A5 (https=)
JP2005521713A5 (https=)
JP2005539088A5 (https=)
EP0931786A3 (en) Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP2006143751A5 (https=)
JP2010523476A5 (https=)
JP2010540593A5 (https=)
JP2005523922A5 (https=)
JP2004516314A5 (https=)
JP2007508359A5 (https=)
JP2004530641A5 (https=)
JP2002526516A5 (https=)
JP2009529540A5 (https=)
JP2004534774A5 (https=)
JP2010530881A5 (https=)
JP2007514773A5 (https=)
JP2010090149A5 (https=)
JP2009536221A5 (https=)
JP2013514980A5 (https=)
JP2009537540A5 (https=)
JP2008536833A5 (https=)
JP2010155827A5 (https=)
JP2004502732A5 (https=)